TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

TuHURA Biosciences, Inc. (NASDAQ:HURA) has received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $9.00.

A number of equities research analysts have recently issued reports on the stock. Citigroup began coverage on shares of TuHURA Biosciences in a report on Monday, April 27th. They set an “outperform” rating on the stock. Citizens Jmp assumed coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued a “market outperform” rating and a $9.00 price objective for the company. Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, May 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Friday, July 17th.

TuHURA Biosciences Stock Down 7.7%

NASDAQ:HURA opened at $2.28 on Tuesday. The stock has a fifty day simple moving average of $2.29 and a 200 day simple moving average of $2.02. The firm has a market capitalization of $145.19 million, a price-to-earnings ratio of -4.22 and a beta of -0.01. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $3.43.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. Equities analysts predict that TuHURA Biosciences will post -0.56 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Bank of America Corp DE purchased a new stake in TuHURA Biosciences in the 4th quarter worth about $59,000. Jane Street Group LLC purchased a new position in TuHURA Biosciences during the 1st quarter valued at about $69,000. Geode Capital Management LLC increased its holdings in shares of TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after purchasing an additional 307,260 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of TuHURA Biosciences in the 2nd quarter valued at about $27,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of TuHURA Biosciences in the second quarter worth approximately $97,000. 0.62% of the stock is owned by institutional investors and hedge funds.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.